nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2020 | editorial

Treating head and neck cancer—A multidisciplinary effort

verfasst von: Gabriele Gamerith, MD, Assoc. Prof. PD Dr. Thorsten Fuereder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Excerpt

Head and neck (HNC) is the tenth most common cancer worldwide with over 650,000 new cases per year [1‐3]. The major risk factors for development of squamous cell HNC comprise alcohol and tobacco consumption [4]. During the last few decades human papilloma virus (HPV) infection has been identified to contribute to the development of oropharyngeal HNC in a younger subgroup of patients [5]. This population shows a more favorable prognosis compared to HPV-negative disease [5]. Standard treatment options for HNC independent of HPV status include surgery, standard radiation, chemo- or bioradiation and chemotherapy. …

Vorheriger Artikel Homologous recombination deficiency: New biomarkers in innovative treatments

Nächster Artikel Fertility preservation

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef

Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.CrossRef

Pfister DG, Ang KK, Brizel DM, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:917–23.CrossRef

World Health Organization, International Agency for Research on Cancer. Alcohol consumption and ethyl carbamate. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 96. 2010. pp. 3–1383.

Tornesello ML, Perri F, Buonaguro L, Ionna F, Buonaguro FM, Caponigro F. HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches. Cancer Lett. 2014;351:198–205.CrossRef

Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73:187–90.CrossRef

Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104:946–54.CrossRef

Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–vii61.CrossRef

Strobl A, Hartl M, Burian M. Transoral robotic surgery in head and neck cancer. memo. 2020;13(4). https://doi.org/10.1007/s12254-020-00638-5.CrossRef

10.

Georg P. Particle therapy in head and neck cancer—expanding therapeutic options. memo. 2020;13(4). https://doi.org/10.1007/s12254-020-00623-y.CrossRef

11.

Kloppenburg M, Mildner F, Kasseroler MT, Dejaco D, Amann A. Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC). memo. 2020;13(4). https://doi.org/10.1007/s12254-020-00645-6.CrossRef

12.

Minichsdorfer C. Systemic therapy for metastatic salivary gland tumors—challenges and novel concepts. memo. 2020;13(4). https://doi.org/10.1007/s12254-020-00614-z.CrossRef

13.

Wagner C. Nutritional management during treatment for head and neck cancer. memo. 2020;13(4). https://doi.org/10.1007/s12254-020-00613-0.CrossRef

Titel: Treating head and neck cancer—A multidisciplinary effort
verfasst von: Gabriele Gamerith, MD
Assoc. Prof. PD Dr. Thorsten Fuereder
Publikationsdatum: 01.12.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00656-3

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer

Homologous recombination deficiency: New biomarkers in innovative treatments

Molecular profiling in gastroesophageal cancer—clinical routine and future perspective

Homologous recombination deficiency in epithelial ovarian cancer